New hope for tough prostate cancer: targeted radiation drug enters phase 2 trial
NCT ID NCT06402331
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new radioactive drug, FPI-2265, in 110 men with a hard-to-treat type of prostate cancer that has spread and stopped responding to standard hormone therapy. Participants must have already received a similar radioactive treatment. The goal is to find the safest dose and see if it can shrink tumors or lower PSA levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BAMF Health
Grand Rapids, Michigan, 49503, United States
-
Biogenix Molecular, LLC
Miami, Florida, 33165, United States
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Hoag Health Center Irvine
Irvine, California, 92618, United States
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016, United States
-
Memorial Sloan Kettering Cancer Center - NYC
New York, New York, 10065, United States
-
New Mexico Oncology Hematology Consultants Ltd.
Albuquerque, New Mexico, 87109, United States
-
Oregon Health and Science University (OHSU, Knight Cancer Center)
Portland, Oregon, 97239-3098, United States
-
SSM Health Saint Louis University Hospital
St Louis, Missouri, 63104, United States
-
The University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
U.T. MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UCSF School of Medicine
San Francisco, California, 94143, United States
-
United Theranostics
Glen Burnie, Maryland, 21061, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
-
VA Greater Los Angeles Healthcare System
Los Angeles, California, 90073, United States
-
VA North Texas Health Care System, Nuclear Medicine Service
Dallas, Texas, 75216, United States
-
XCancer
Omaha, Nebraska, 68130, United States